Enveric Biosciences (ENVB) Free Cash Flow (2010 - 2026)
Enveric Biosciences (ENVB) posted Free Cash Flow of -$2.3 million for Q1 2026, down 26.44% sequentially from -$1.8 million in Q4 2025, and up 5.63% YoY from -$2.1 million in Q1 2025.
Enveric Biosciences (ENVB) Free Cash Flow (2010 - 2026) Analysis & Trends
Enveric Biosciences has reported Free Cash Flow for 17 years, with the latest figure at -$2.3 million in Q1 2026.
- Quarterly Free Cash Flow rose 5.63% year-over-year to -$2.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$8.0 million (down 6.48% YoY) and the FY2025 annual result came in at -$8.1 million, down 5.38% from the prior year.
- Free Cash Flow retreated to -$2.3 million in Q1 2026 per ENVB's latest filing, from -$1.8 million in the prior quarter.
- Over five years, Free Cash Flow peaked at -$927070.0 in Q3 2024 and troughed at -$5.1 million in Q1 2023.
- A 5-year average of -$2.9 million and a median of -$2.6 million in 2024 frame the typical range for Free Cash Flow.
- The sharpest annual moves came in 2022 and 2024: Free Cash Flow sank 129.44% in 2022, then jumped 66.17% in 2024.
- Over 5 years, Free Cash Flow stood at -$3.5 million in 2022, then soared by 49.51% to -$1.8 million in 2023, then rose by 25.1% to -$1.3 million in 2024, then plunged by 36.09% to -$1.8 million in 2025, then slipped by 26.44% to -$2.3 million in 2026.
- According to Business Quant data, Free Cash Flow over the past three periods registered -$2.3 million, -$1.8 million, and -$2.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -563.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 437.80 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 292.04 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -95.09 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 477.44 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 433.84 Mn |
| 10 | Enveric Biosciences | 5.42 Mn | -2.87 Mn | - | -2.44 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2.26 Mn |
| Mar 31, 2026 | -2.26 Mn |
| Dec 31, 2025 | -1.78 Mn |
| Dec 31, 2025 | -1.78 Mn |
| Sep 30, 2025 | -2.07 Mn |
| Sep 30, 2025 | -2.07 Mn |
| Jun 30, 2025 | -1.89 Mn |
| Jun 30, 2025 | -1.89 Mn |
| Mar 31, 2025 | -2.39 Mn |
| Mar 31, 2025 | -2.39 Mn |
| Dec 31, 2024 | -1.31 Mn |
| Dec 31, 2024 | -1.31 Mn |
| Sep 30, 2024 | -927,070.00 |
| Sep 30, 2024 | -927,070.00 |
| Jun 30, 2024 | -2.89 Mn |
| Jun 30, 2024 | -2.89 Mn |
| Mar 31, 2024 | -2.60 Mn |
| Mar 31, 2024 | -2.60 Mn |
| Dec 31, 2023 | -1.75 Mn |
| Dec 31, 2023 | -1.75 Mn |